Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Quick Stats
53.3
AI Score
HOLD0.08
Volume Ratio
Next Earnings
13
+ve Days (30d)
16
-ve Days (30d)
RADX Stock Summary
Last updated Jan 27, 2026
RADX is currently trading at $4.872, positioned below its 200-day moving average of $, suggesting bearish momentum. The stock has a 52-week range of $3.4962 to $16.25.
Technical Analysis: The 50-day moving average stands at $, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 47.064, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.156, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates RADX at 53.3/100 with a HOLD recommendation.
RADX (Radiopharm Theranostics Limited American Depositary Shares) Indicators
Last updated Jan 27, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 47.064 |
| CMF (20) | -0.156 |
| ROC (10) | -4.466 |
| ADX (14) | 25.109 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.059 |
| AROONOSC (14) | 42.857 |
| WILLAMS %R (14) | -60.317 |
| MFI (14) | 50.07 |
RADX Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
RADX Price vs Max Options Open Interest
RADX Max Change In Options Open Interest
RADX Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
RADX Daily Out of Money Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
RADX Daily In the Money Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
RADX Most Active Options by Volume(near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Radiopharm Theranostics Limited American Depositary Shares is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
RADX Moving Averages Analysis
RADX (Radiopharm Theranostics Limited American Depositary Shares) Simple Moving Averages
Moving Averages are last updated
| Days | MA |
|---|
RADX Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 39.8 million |
| Earnings/Share ($) | -3.72 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -3.285 |
| EPS Estimate Next Year ($) | -3.66 |
| WallStreet Target Price ($) | 18.1791 |
| Most Recent Quarter |